NDA 16-023/SLR-035
NDA 18-101/SLR-007

Endo Pharmaceuticals Inc.
Attention: Ira C. Lentz
Manager, Regulatory Affairs-Labeling
223 Wilmington West Chester Pike
Chadds Ford, PA 19317

Dear Mr. Lentz:

Please refer to your Labeling Supplement-Changes Being Effected, dated September 11, 2000, received September 12, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Symmetrel® (Amantadine Hydrochloride) Tablets and Syrup.

Reference is also made to the April 7, 2000 telephone facsimile from the Division of Antiviral Drug Products requesting that you submit a labeling supplement with: 1) proposed language to caution prescribers that potentially lethal overdoses may occur with amantadine quantities lower than the lethal dose described in the current labeling, and 2) the following information in the PRECAUTIONS section of the label: "Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza. Symmetrel® has not been shown to prevent such complications."

This Labeling Supplement-Changes Being Effected provides for the requested revisions to the **PRECAUTIONS** section of the Symmetrel® label and changes to the **WARNINGS** and **OVERDOSAGE** sections of the Symmetrel® label.

We have completed review of this supplemental application and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon labeling text. Accordingly, this supplemental application is approved effective on the date of this letter. However, in order to comply with 21 CFR 201.10(g)(1), we request that you add the established drug name, amantadine hydrochloride, in conjunction with the proprietary name, to the last page of the label at the time of your next printing, as agreed to in our teleconference on November 29, 2000.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Virginia L. Yoerg, Regulatory Project Manager, at (301) 827-2335.

Sincerely,

Debra B. Birnkrant, M.D.
Acting Director
Division of Antiviral Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research